Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal

dc.contributor.author	Mujica-mota, R
dc.contributor.author	Varley-Campbell, J
dc.contributor.author	Tikhonova, I
dc.contributor.author	Cooper, C
dc.contributor.author	Hoyle, MW
dc.contributor.author	Rudin, C
dc.contributor.author	Rule, S
dc.contributor.author	Snowsill, T
dc.date.accessioned	2016-06-27T14:00:03Z
dc.date.issued	2016-02-10
dc.description.abstract	Report commissioned by the NIHR HTA Programme	en_GB
dc.description.sponsorship	This report was commissioned by the NIHR HTA Programme as project number 15/64/10.	en_GB
dc.identifier.citation	Mujica Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Hoyle M, Rudin C, Snowsill T. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal. Peninsula Technology Assessment Group (PenTAG), 2016.	en_GB
dc.identifier.uri	http://hdl.handle.net/10871/22268
dc.language.iso	en	en_GB
dc.publisher	Peninsula Technology Assessment Group (PenTAG), University of Exeter	en_GB
dc.relation.url	https://www.nice.org.uk/guidance/GID-TA10000/documents/committee-papers	en_GB
dc.title	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal	en_GB
dc.type	Report	en_GB
dc.date.available	2016-06-27T14:00:03Z
exeter.confidential	false	en_GB